advertisement
Abstract #78540 Published in IGR 20-1
Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents
Stahnke T; Siewert S; Reske T; Schmidt W; Schmitz KP; Grabow N; Guthoff RF; Wree ABioscience reports 2018; 38:
To prevent implant failure due to fibrosis is a major objective in glaucoma research. The present study investigated the antifibrotic effects of paclitaxel (PTX), caffeic acid phenethyl ester (CAPE), and pirfenidone (PFD) coated microstent test specimens in a rat model. Test specimens based on a biodegradable blend of poly(4-hydroxybutyrate) biopolymer and atactic poly(3-hydroxybutyrate) (at.P(3HB)) were manufactured, equipped with local drug delivery (LDD) coatings, and implanted in the subcutaneous white fat depot. Postoperatively, test specimens were explanted and analyzed for residual drug content. Fat depots including the test specimens were histologically analyzed. drug release studies revealed an initial burst for LDD devices. , slow drug release of PTX was found, whereas it already completed 1 week postoperatively for CAPE and PFD LDD devices. Histological examinations revealed a massive cell infiltration in the periphery of the test specimens. Compact fibrotic capsules around the LDD devices were detectable at 4-36 weeks and least pronounced around PFD-coated specimens. Capsules stained positive for extracellular matrix (ECM) components. The presented model offers possibilities to investigate release kinetics and the antifibrotic potential of drugs as well as the identification of more effective agents for a novel generation of drug-eluting glaucoma microstents.
Department of Ophthalmology, Rostock University Medical Center, Doberaner Str. 140, Rostock 18057, Germany thomas.stahnke@med.uni-rostock.de.
Full articleClassification:
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
